1073 related articles for article (PubMed ID: 17785729)
1. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
[TBL] [Abstract][Full Text] [Related]
2. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM
J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342
[TBL] [Abstract][Full Text] [Related]
3. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
4. Near infrared fluorescent optical imaging for nodal staging.
Sampath L; Wang W; Sevick-Muraca EM
J Biomed Opt; 2008; 13(4):041312. PubMed ID: 19021320
[TBL] [Abstract][Full Text] [Related]
5. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer.
Reilly RM; Kiarash R; Sandhu J; Lee YW; Cameron RG; Hendler A; Vallis K; Gariépy J
J Nucl Med; 2000 May; 41(5):903-11. PubMed ID: 10809207
[TBL] [Abstract][Full Text] [Related]
6. MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using ¹¹¹In-labeled bispecific radioimmunoconjugates.
Razumienko E; Dryden L; Scollard D; Reilly RM
Breast Cancer Res Treat; 2013 Apr; 138(3):709-18. PubMed ID: 23525982
[TBL] [Abstract][Full Text] [Related]
7. A kit to prepare (111)In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer.
Scollard DA; Chan C; Holloway CM; Reilly RM
Nucl Med Biol; 2011 Jan; 38(1):129-36. PubMed ID: 21220136
[TBL] [Abstract][Full Text] [Related]
8. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments.
Tang Y; Wang J; Scollard DA; Mondal H; Holloway C; Kahn HJ; Reilly RM
Nucl Med Biol; 2005 Jan; 32(1):51-8. PubMed ID: 15691661
[TBL] [Abstract][Full Text] [Related]
9. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
Razumienko EJ; Scollard DA; Reilly RM
J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164
[TBL] [Abstract][Full Text] [Related]
10. Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts.
McLarty K; Cornelissen B; Scollard DA; Done SJ; Chun K; Reilly RM
Eur J Nucl Med Mol Imaging; 2009 Jan; 36(1):81-93. PubMed ID: 18712381
[TBL] [Abstract][Full Text] [Related]
11. Conjugation with (111)In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225.
Wen X; Wu QP; Ke S; Ellis L; Charnsangavej C; Delpassand AS; Wallace S; Li C
J Nucl Med; 2001 Oct; 42(10):1530-7. PubMed ID: 11585869
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts.
Costantini DL; McLarty K; Lee H; Done SJ; Vallis KA; Reilly RM
J Nucl Med; 2010 Jul; 51(7):1084-91. PubMed ID: 20554744
[TBL] [Abstract][Full Text] [Related]
13. Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody.
Malmberg J; Sandström M; Wester K; Tolmachev V; Orlova A
Nucl Med Biol; 2011 Nov; 38(8):1093-102. PubMed ID: 22137850
[TBL] [Abstract][Full Text] [Related]
14. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
[TBL] [Abstract][Full Text] [Related]
15. ¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer.
Fasih A; Fonge H; Cai Z; Leyton JV; Tikhomirov I; Done SJ; Reilly RM
Breast Cancer Res Treat; 2012 Aug; 135(1):189-200. PubMed ID: 22736376
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of [¹¹¹ In]-DOTA-trastuzumab for clinical trials.
Alirezapour B; Jalilian AR; Rajabifar S; Mirzaii M; Moradkhani S; Pouladi M; Aslani G
J Cancer Res Ther; 2014; 10(1):112-20. PubMed ID: 24762497
[TBL] [Abstract][Full Text] [Related]
17. Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe.
Li C; Wang W; Wu Q; Ke S; Houston J; Sevick-Muraca E; Dong L; Chow D; Charnsangavej C; Gelovani JG
Nucl Med Biol; 2006 Apr; 33(3):349-58. PubMed ID: 16631083
[TBL] [Abstract][Full Text] [Related]
18. Preparation and
Okarvi SM; Aljammaz I
Anticancer Res; 2018 May; 38(5):2823-2830. PubMed ID: 29715105
[TBL] [Abstract][Full Text] [Related]
19. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies.
Terwisscha van Scheltinga AG; van Dam GM; Nagengast WB; Ntziachristos V; Hollema H; Herek JL; Schröder CP; Kosterink JG; Lub-de Hoog MN; de Vries EG
J Nucl Med; 2011 Nov; 52(11):1778-85. PubMed ID: 21990576
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
